{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"15","upperLimit":"176","value":"40"},{"groupId":"OG001","lowerLimit":"9","upperLimit":"431","value":"100"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"description":"Time to response was defined as the interval between the first date of treatment and the first notation of response.","dispersionType":"Full Range","groups":[{"description":"CTCL patients will receive 1000 mg/m2 of PXD101 IV\n\nbelinostat: 1000 mg/m2 for 5 days every 21 days; IV","id":"OG000","title":"Arm A (CTCL, ITT Population)"},{"description":"PTCL patients will receive 1000 mg/m2 of PXD101 IV\n\nbelinostat: 1000 mg/m2 for 5 days every 21 days; IV","id":"OG001","title":"Arm B (PTCL, ITT Population)"}],"paramType":"MEDIAN","populationDescription":"Time to response (ITT population) was estimated using the Kaplan-Meier method for CTCL and PTCL arms. For 4 patients with CTCL and 6 patients with PTCL, response was recorded. The median time to response and the full range (days) are presented.","reportingStatus":"POSTED","timeFrame":"throughout the study, or for a maximum of 2 years","title":"Time to Response","type":"SECONDARY","unitOfMeasure":"Days"}